PMC:7306567 / 17450-17641 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T21","span":{"begin":45,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A21","pred":"fma_id","subj":"T21","obj":"http://purl.org/sig/ont/fma/fma62970"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"LitCovid-PubTator","denotations":[{"id":"193","span":{"begin":4,"end":17},"obj":"Chemical"}],"attributes":[{"id":"A193","pred":"tao:has_database_id","subj":"193","obj":"MESH:C508735"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T113","span":{"begin":45,"end":51},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T114","span":{"begin":137,"end":138},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":4,"end":17},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_85979"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T116","span":{"begin":0,"end":191},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T139","span":{"begin":4,"end":17},"obj":"CHEBI:85979;CHEBI:85979"},{"id":"T140","span":{"begin":45,"end":51},"obj":"UBERON:0001969"},{"id":"T73675","span":{"begin":4,"end":17},"obj":"CHEBI:85979;CHEBI:85979"},{"id":"T42840","span":{"begin":45,"end":51},"obj":"UBERON:0001969"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}

{"project":"2_test","denotations":[{"id":"32572532-29544767-47963441","span":{"begin":187,"end":189},"obj":"29544767"},{"id":"T51946","span":{"begin":187,"end":189},"obj":"29544767"}],"text":"For isavuconazole, there is no robust target plasma concentration, and the population average exposure of participants that demonstrated a favorable response (2–4 mg/L) is commonly used [43]."}